Arbutus Biopharma Corp. buy Maxi_Scalibusa
Start price
16.11.20
/
50%
€3.45
Target price
16.11.21
-
Performance (%)
-14.81%
End price
17.11.21
€2.94
Summary
This prediction ended on 17.11.21 with a price of €2.94. The price of Arbutus Biopharma Corp. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -14.81%. Maxi_Scalibusa has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Arbutus Biopharma Corp. | 5.643% | 5.643% | 17.272% | 55.422% |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% | 65.510% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% | 95.368% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% | 42.232% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% | 59.132% |
According to Maxi_Scalibusa what are the pros and cons of Arbutus Biopharma Corp. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Cons
Comments by Maxi_Scalibusa for this prediction
In the thread Arbutus Biopharma Corp. diskutieren
Buy Arbutus Biopharma Corp.
In the thread Trading Arbutus Biopharma Corp.
Die von Maxi_Scalibusa gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Maxi_Scalibusa for Arbutus Biopharma Corp.
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€4.85
01.12.21
01.12.21
-
01.12.22
01.12.22
-53.67%
02.12.22
02.12.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
